NitroVest
Research type
Research Study
Full title
Investigating nitroglycerin as a trigger for episodes of dizziness in patients with migraine and other neuro-otological disorders associated to dizziness.
IRAS ID
312478
Contact name
Maria Dolores Villar Martinez
Contact email
Sponsor organisation
King's College London
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
Vestibular migraine is a subtype of migraine consisting of severe, debilitating attacks of dizziness or vertigo in people who also suffer from migraine. In our group, previous observational studies have shown that more than half of migraineurs suffer from dizziness during their attacks, and given that migraine prevalence can be up to 25% in the UK, vestibular migraine is a very frequent and probably underestimated condition. Nitroglycerin is a recognised drug capable of triggering migraine, as well as other symptoms associated to the migraine attack, such as nausea or sensitivity to light, and has been extensively used by our group in previous studies. These have shown that more than 75% of migraineurs could trigger vertigo or dizziness among their symptoms associated to the migraine episode when using nitroglycerine. The aim of NitroVest is to assess if the vestibular symptoms reported by these patients are directly related to a migraine attack, by means of characterising these episodes from a neuro-otological point of view, and compare the triggering effects in these subjects with those suffering from other conditions that include episodes of vertigo, such as benign paroxysmal positional vertigo, where their symptoms are definitely not due to migraine, but due to a mechanical cause.
REC name
London - Westminster Research Ethics Committee
REC reference
23/PR/1402
Date of REC Opinion
16 Feb 2024
REC opinion
Further Information Favourable Opinion